Therapeutic potential and mechanistic insights of silibinin targeting cancer-associated fibroblasts in colorectal cancer
Authors:
Open Access
- 2 April 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1527871
Abstract
Objective: This study aims to elucidate the role of SB in inhibiting CRC progression by targeting CAFs and elucidating the underlying mechanisms.Methods: In this study, a spontaneous CRC model induced by AOM/DSS was used to evaluate the effects of SB on CAFs. Mice were treated with SB, and tumor burden was assessed by colon length. CAFs were isolated post-treatment for transcriptomic analysis to identify differentially expressed genes, with molecular docking providing in silico evidence of SB’s binding to target proteins. CAFs changes were further examined through HE staining, IHC, and assays for cell viability, colony formation, and migration. Integrated bioinformatic analysis elucidated the mechanistic role of SB in CAFs-mediated CRC progression.Results: In vivo studies showed that SB effectively reduced POSTN and α-SMA protein levels in CAFs in AOM/DSS-induced CRC mice. Consistently, in vitro experiments demonstrated that SB significantly decreased both protein and mRNA levels of α-SMA and POSTN in fibroblasts (colonic myofibroblast CCD-18Co cell lines.) co-cultured with CRC cell lines (human colorectal adenocarcinoma SW480 and RKO cell lines). SB also inhibited proliferation, colony formation, and migration of CCD-18Co cells. Transcriptomic and integrated bioinformatic analyses further suggested that SB exerts therapeutic effects on CAFs in CRC by modulating key target pathways.Conclusion: These results demonstrated that SB holds promise as a therapeutic agent for targeting CAFs in CRC. This study advances our understanding of SB’s mechanisms, particularly its inhibitory effects on CAFs proliferation, colony formation, and migration.Keywords
Funding Information
- National Natural Science Foundation of China
- Shanghai Science and Technology Development Foundation
This publication has 29 references indexed in Scilit:
- Chinese herbal Jianpi Jiedu formula suppressed colorectal cancer growth in vitro and in vivo via modulating hypoxia-inducible factor 1 alpha-mediated fibroblasts activationJournal of Ethnopharmacology, 2024
- Cancer-associated fibroblasts are the main contributors to epithelial-to-mesenchymal signatures in the tumor microenvironmentScientific Reports, 2023
- Path of Silibinin from diet to medicine: A dietary polyphenolic flavonoid having potential anti-cancer therapeutic significanceSeminars in Cancer Biology, 2021
- Tumor microenvironment as a therapeutic target in cancerPharmacology & Therapeutics, 2020
- A framework for advancing our understanding of cancer-associated fibroblastsNature Reviews Cancer, 2020
- The great escape: tumour cell plasticity in resistance to targeted therapyNature Reviews Drug Discovery, 2019
- Silibinin to improve cancer therapeutic, as an apoptotic inducer, autophagy modulator, cell cycle inhibitor, and microRNAs regulatorLife Sciences, 2018
- A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patientsInvestigational New Drugs, 2006
- Therapeutic targeting of the tumor microenvironmentCancer Cell, 2005
- Targeted recycling of PECAM from endothelial surface-connected compartments during diapedesisNature, 2003